Faeth Therapeutics (FTH) Return on Assets (2021 - 2026)

Faeth Therapeutics' (FTH) quarterly Return on Assets came in at 0.02% in Q1 2026, down 139.38% on a QoQ basis from 0.01% in Q4 2025.

Faeth Therapeutics (FTH) Return on Assets (2021 - 2026) Analysis & Trends

Faeth Therapeutics (FTH) has 6 years of Return on Assets data on file, last reported at 0.02% in Q1 2026.

Quarterly Return on Assets changed N/A year-over-year to 0.02% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.02% (changed N/A YoY) and the FY2025 annual result came in at 0.02%, down 1.0% from the prior year.
Return on Assets slipped to 0.02% in Q1 2026, from 0.01% in the prior quarter.
In the past five years, Return on Assets ranged from a high of 0.0% in Q2 2022 to a low of 0.02% in Q1 2026.
A 5-year average of 0.01% and a median of 0.01% in 2024 frame the typical range for Return on Assets.
The widest YoY moves for Return on Assets: up 0 bps in 2022, down 0 bps in 2022.
Tracing FTH's Return on Assets over 5 years: stood at 0.0% in 2022, then declined by 10 bps to 0.01% in 2023, then sank by 53 bps to 0.01% in 2024, then retreated by 28 bps to 0.01% in 2025, then plunged by 139 bps to 0.02% in 2026.
The last three Return on Assets figures came in at 0.02% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROA (Qtr)
1	Vertex Pharmaceuticals	138.90 Bn	131.05 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	86.10 Bn	78.11 Bn	3.93 Bn	0.00%
3	Argenx Se	65.56 Bn	60.37 Bn	1.37 Bn	-
4	Moderna	55.82 Bn	50.68 Bn	52.00 Mn	0.00%
5	BeOne Medicines	42.14 Bn	37.04 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.67 Bn	28.36 Bn	992.69 Mn	0.00%
7	BioNTech SE	27.74 Bn	9.35 Bn	668.28 Mn	0.00%
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.38 Bn	26.54 Bn	-	0.00%
10	Faeth Therapeutics	179.96 Mn	179.96 Mn	-	-0.01%

Download Data